FDC has announced that it has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Cefixime for Oral Suspension USP. The approval covers two dosage strengths: 100 mg/5 mL and 200 mg/5 mL.
This development marks a significant milestone for FDC as it expands its portfolio of approved pharmaceuticals in the United States market. Cefixime is an antibiotic used to treat a variety of bacterial infections, and its approval in oral suspension form offers a convenient option for patients, particularly children, who may have difficulty swallowing tablets.
The approval by the USFDA is a testament to FDC’s commitment to maintaining high standards in pharmaceutical manufacturing and its ability to meet stringent regulatory requirements. This achievement is expected to enhance FDC’s presence in the US market and contribute to the company’s growth strategy.
FDC’s successful ANDA approval for Cefixime oral suspension underscores the company’s focus on increasing its portfolio of generic drugs available in international markets, thereby strengthening its position in the global pharmaceutical industry.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).